TRADITIONDATA
10.10.2022 13:43:42 CEST | Business Wire | Pressemeddelelse
TraditionDATA, data- og informationsserviceafdelingen hos Compagnie Financière Tradition (Tradition), har udgivet en omfattende skandinavisk datapakke som svar på den stigende efterspørgsel på Traditions markedsførende prisdata i regionen.
Den fulde pakke af skandinaviske data, som indeholder data om valuta (FX), rentederivater (IRD) og inflation, er baseret på en kombination af priser, der tager udgangspunkt i aktiehandler foretaget af Traditions markedsførende mæglere samt deres ekspertanalyser. Dataene er tilgængelige direkte fra TraditionDATA såvel som på Refinitiv under firmaets regionale markedsdatapakker.
Udgivelsen af den skandinaviske datapakke er i tråd med TraditionDATAs mission om at tilbyde mindre, granulære pakker baseret på valuta, region eller produkt, som gør det muligt for kunderne kun at betale for det, de rent faktisk har brug for. Dette er i direkte modsætning til mange af deres konkurrenter, som kun tilbyder større europæiske pakker, som er dyre og tager tid at analysere nærmere, før de kan konverteres til brugbar forretningsindsigt.
Den skandinaviske datapakke giver kunderne mulighed for at analysere:
- FX - spothandler, krydshandler (cross trades), terminshandler på ydelser og produkter og kvartalsindtjening på tværs af DKK, NOK og SEK på det internationale valutamarked
- IRD - basisderivater, krydsvalutaderivater, renteswaps, overnight indexed swaps, terminskursaftaler
- Inflation - forbrugerprisindeksdata om inflation
Udover at tilbyde kunderne avancerede data og ekspertise i den skandinaviske region, muliggør TraditionDATA også streaming i realtid, øjebliksbilleder af dag til dag-renter, adgang til historiske data og fuld integration med eksisterende arbejdsgange.
James Watson, Global Head of Sales hos TraditionDATA, kommenterede: “Hos TraditionDATA ved vi, at der ikke findes to ens virksomheder, og derfor arbejder vi sammen med vores kunder om at udvikle pakker, der er skræddersyede til deres individuelle behov. Vi tror på, at regionale markeder fortsat vil kræve specifikke datasæt, der er lokaliseret til deres overordnede forretningsaktiviteter, og denne tilgang har allerede vist sig at være en stor succes i forbindelse med vores japanske Nihon- og israelske Shekel-pakker. Vi ser frem til at fortsætte med at tilføje nye instrumenter til den skandinaviske pakke og udvide vores regionale markedsdatatilbud i de kommende måneder.”
ENDS
Om TraditionDATA
TraditionDATA tilbyder en varieret og fleksibel tilgang til leverance af markedsdata på tværs af alle aktivklasser på det globale uofficielle børsmarked for derivater.
Ved at tilbyde mindre, mere fokuserede og granulære pakker baseret på valuta, region eller produkt sætter TraditionDATA sine kunder i stand til at betale for netop det, de har brug for, i modsætning til større pakker, der kræver nærmere analyse.
Med over 1 billion datapunkter på tværs af mere end 200 produkter og 186.000 instrumenter, der går mere end 15 år tilbage, samt 43 kontorer i 30 lande, tilbyder TraditionDATA aktører på tværs af det globale finansmarked alle de oplysninger, de har brug for, for at drive deres forretning og tage forretningsmæssige beslutninger, på grundlag af et stadigt voksende datasæt.
TraditionDATA er en del af Tradition (Compagnie Financière Tradition S.A. (SWX: CFT)), en af verdens største børsmæglere inden for finansielle og råvarerelaterede produkter på det uofficielle børsmarked for værdipapirer. Traditions lange historie med administration af prissætning af likviditet og afvikling af handler på tværs af flere aktivklasser med både nye og komplekse produkter på primære og nye vækstmarkeder gør det muligt for TraditionDATA at prisfastsætte finansielle instrumenter på mange af verdens mest omskiftelige markeder, som andre ikke formår.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20221010005055/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
